MedTrace Logo

Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

NCT03510741 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2022-04-27

No results posted yet for this study

Summary

This study aims to determine if the addition of Sodium Benzoate and / or NAC to TAU will be acceptable and tolerable and result in overall improvement of symptoms, social and cognitive functioning in patients with early schizophrenia spectrum disorder.

Conditions

  • Schizophrenia
  • Schizophreniform Disorders
  • Schizoaffective Disorder

Interventions

DRUG

Sodium Benzoate

Sodium Benzoate will be administered at 1000mg daily

DRUG

N-Acetylcysteine

N-Acetylcysteine 1000 mgs twice daily dose

DRUG

Placebo

Placebo added to TAU

DRUG

Sodium Benzoate Plus N-Acetylcysteine

Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose

Sponsors & Collaborators

  • Pakistan Institute of Living and Learning

    lead OTHER

Principal Investigators

  • Imran B Chaudhry, MD · Ziauddin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-30
Completion
2021-03-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03510741 on ClinicalTrials.gov